European private equity outfit Cinven has stepped up to buy the majority of long-rumored target Medpace, trading $915 million for an undisclosed controlling stake in the CRO.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
SAN FRANCISCO--Another J.P. Morgan Healthcare Conference is in the books, and biopharma's movers, shakers and up-and-comers have headed back to Boston, Basel and Bangalore. This year, in the shadow of the best market for biotech IPOs since 2000, there's fresh optimism that capital will continue to flow into drug developers' pockets, whether via more market debuts or through the many top-tier VCs putting together new funds.
To no one's surprise, cancer immunotherapies are hogging much of the spotlight, but Intercept's explosive week put NASH near the top of the list of biopharma buzzwords, and a host of promising RNA therapies from companies big and small grabbed some headlines. Through it all, the Fierce team was darting in and out of presentations, one-on-ones and cafe chats in and around Union Square to bring you this, our annual industry barometer.
POPULAR COMMENT THREADS
Global CRO Covance boosted its revenue by about 11% last quarter, capping off a banner year in which the company outstripped its financial targets.
Quintiles founder Dennis Gillings and a trio of private equity backers hauled in more than $400 million when the company first went public, and now they're looking to reap nearly $1 billion more in a secondary public offering.
After numerous setbacks and transitional moves, Columbia Laboratories has settled into its new identity as a CRO, closing its first full quarter of CRO revenue and plotting a brighter future.
INC Research is doubling down on the Middle East, buying up a longtime partner to tighten its grip on a region the CRO says is rapidly developing into a go-to market for clinical research.
WuXi PharmaTech boosted its revenue 15.6% last year, and China's largest CRO is expecting to match that growth in the new year, counting on steady demand for manufacturing and a larger share of the U.S. research market.
Early-phase CRO Celerion is expanding its reach into South Korea, partnering up with a local hospital to run trials in the country's fast-growing market for clinical research.
From Our Sister Sites
The National Institute of Allergy and Infectious Diseases has awarded a 7-year, $9.8 million grant to develop an AIDS vaccine to four Seattle-based research organizations and Rockefeller University.
A British drugmaker has landed in the middle of the controversy over Sweetwater, Texas' Rattlesnake RoundUp